Treatment of resistant disease

Leukemia

Volumn 12, Issue SUPPL. 1, 1998, Pages

  Schiller, Gary J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Refractory leukemia; Relapsed leukemia

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CYTOGENETICS; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SURVIVAL RATE;

EID: 0031756061     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Forman SJ, Nademanee AP, O'Donnell MR, et al. High-dose cytosine arabinoside and daunomycin as primary therapy for adults with acute nonlymphoblastic leukemia: a pilot study. Semin Oncol 1985;12(suppl3):114-116.
2. Champlin R. Bone Marrow Transplantation for Acute Myelogenous Leukemia: Recent Advances. Bone Marrow Transplantation: Current Controversies. Alan R Liss: New York, NY:1989;95-106.
3. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991;9:1210-1214.
4. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997;40(suppl):S9-S12.
5. Capizzi RL, Powell BL, Cooper MR, et al. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. Semin Oncol 1985:12(supp13):105-113.
6. Carella AM, Carlier P, Pungolino E, et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993;7:196-199.
7. Gore M, Powles R, Lakhani A, et al. Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother Pharmacol 1989;23:373-376.
8. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study. Onkologie 1986;9:144-146.
9. Kusnierz-Glaz CR, Normann D, Weinberg R, et al. Subcutaneous low-dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 1993;11:73-80.
10. Reece DE, Elmongy MB, Barnett MJ, Klingemann H-G, Shepherd JD, Phillips GL. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. Cancer Invest 1993;11:509-516.
11. Takaku F, Urabe A, Mizoguchi H, et al. High-dose cytosine arabinoside in the treatment of resistant acute leukemia. Semin Oncol 1985;12(suppl 3):144-149.